235 results about "Rat model" patented technology

The invention belongs to the technical field of biology, and particularly relates to casein phosphopeptides for promoting absorption of calcium, iron and zinc minerals and improving bone health. Casein phosphopeptides containing high-activity peptide fragments are obtained through an optimization process, six mineral elements of calcium, magnesium, copper, iron, zinc and manganese serve as research objects, firstly, mineral utilization of CPP is evaluated through a mineral deficiency rat model, the content of Ca, Mg, Cu, Fe, Zn and Mn in thighbones is increased by 7.12%, 3.56%, 20.76%, 15.84%, 9.94% and 67.12% respectively when the CPP is eaten by 7mg / kg.d; secondly, screening a peptide fragment with calcium absorption promoting activity from the CPP by utilizing a molecular docking technology, and performing functional verification; the invention aims to reveal the action effect of CPP in mineral absorption and utilization from cell and animal levels, and provides a theoretical basis for functional development of CPP.

The invention belongs to the technical field of biological medicine, and particularly relates to application of hUC-MSCs combined with Met in preparation of anti-diabetic drugs. The diabetes mellitus is particularly type 2 diabetes mellitus. Through construction of a T2DM rat model, paraffin tissue section detection, serum ELISA, cell experiments and the like, researches prove that T2DM can be effectively treated by HUC-MSCs combined with Met treatment, including reduction of body blood sugar and recovery of blood sugar regulation ability; liver injury caused by T2DM is relieved and repaired; the glycolipid metabolism of the liver of the T2DM rat is improved; the immune inflammation disorder caused by T2DM is relieved; and the apoptosis level of liver cells is improved. And compared with a single hUC-MSCs or Met treatment mode, the combined treatment mode has a better treatment effect. The invention provides a theoretical basis and a new treatment strategy for treatment of T2DM.

The invention discloses application of sodium butyrate in preparation of a medicine for relieving brain injury caused by gas explosion, the sodium butyrate regulates nerve cell ferroptosis through a JNK / P38 MAPK pathway to relieve the brain injury caused by gas explosion, firstly, an animal model of rat brain injury caused by gas explosion is established, and the relation between NaB and brain tissue neuron injury is intervened and observed by applying NaB; secondly, a shock wave physiotherapy instrument is used for impacting a co-culture system of three cells of CTX, H19-7 and GMI-R to simulate explosion to construct an in-vitro experimental model, P38, ERK and Fer-1 inhibitors are adopted for intervention, iron metabolism, ferroptosis and MAPK signal channel factor changes are observed from the cell and molecular level, a mechanism for inhibiting ferroptosis through a related cascade signal channel mediated by NaB-mediated intestinal-brain axis regulation and control is clarified, and the effect of inhibiting ferroptosis is achieved. And a theoretical basis is provided for further explaining the action mechanism of the gas explosion brain injury.

The invention belongs to the technical field of biology, and particularly relates to casein source heptapeptide for promoting calcium absorption and utilization and application of the casein source heptapeptide. The CPP containing the high-activity peptide fragment is obtained through an optimization process, and the influence of the CPP on mineral absorption and conversion is evaluated by utilizing a mineral deficiency rat model; then, heptapeptide with calcium absorption promoting activity is screened out from the CPP in combination with peptiomics and molecular docking technologies, functional verification is carried out, it is found that when the VAPFPEV is 2 mu M, the Ca < 2 + > transport amount is remarkably increased by 25.25%, meanwhile, zebra fish experiments show that intervention of the VAPFPEV effectively reverses reduction of an accumulated optical density value caused by dexamethasone, and compared with a module making set, the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the advantages that the VAPFPEV has the The skull accumulative optical density value of a VAPFPEV (1-20 [mu] M) processing group is obviously increased. It is shown that VAPFPEV can effectively promote Ca < 2 + > transfer and absorption, improve the osteoporosis symptom of zebra fish and increase deposition of calcium in bones.

The invention discloses an application of 4-octyl itaconic acid (4-OI) in preparation of a medicine for improving pulmonary arterial hypertension (PAH). In-vivo experiments show that 4-OI can significantly reduce pulmonary vascular wall thickening and collagen deposition of a PAH rat model, and effectively improve PAH and vascular remodeling. In-vitro experiments further reveal that 4-OI reduces endoplasmic reticulum stress (ERS) by inhibiting a PERK-eIF2alpha pathway, further blocks SM22 dependent smooth muscle cell phenotypic transformation and endothelial-mesenchymal transformation (EndMT) processes, finally inhibits vascular remodeling, and plays a role in treating PAH. The three key pathological processes of ERS, EndMT and vascular remodeling are closely linked, a new perspective is provided for deeply understanding the correlation among oxidative stress, endothelial dysfunction and vascular structure change in PAH, meanwhile, a theoretical foundation is laid for developing PAH and vascular remodeling accurate treatment drugs, and clinical transformation value is achieved.

The invention discloses a polypeptide with blood pressure lowering and oxidation resisting effects as well as a related product and application thereof, and relates to the technical field of biology. According to the invention, casein is taken as a raw material, and the milk-derived active peptide ALPQY is successfully obtained through multi-enzyme hydrolysis, separation, purification and identification. In-vitro activity evaluation results show that the polypeptide not only has strong ACE inhibitory activity, but also can effectively scavenge free radicals; the ACE inhibition IC50 value is 35.56 mu M, the free radical scavenging TEAC value is 1.83 mu mol TE / mu mol, and compared with similar polypeptides, the polypeptide has better ACE inhibition effect and free radical scavenging effect. In-vivo antihypertensive evaluation is carried out through a spontaneous hypertension rat model, it is also shown that the compound has a good antihypertensive effect, and the compound can be used for preparing products related to antihypertensive and / or antioxidation.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The present application relates to the field of model construction, in particular to a kind of construction method of vertebral artery compression rat model, the inner diameter and blood flow velocity of normal rat vertebral artery are obtained by ultrasonic detection;Anesthetize rat, skin preparation, disinfection, incision, expose vertebral artery;According to the required compression degree, select the tissue clip of corresponding specification, fix on vertebral artery, keep vertebral artery in compression state;Suture incision, disinfection, bandage;After rat awakens, daily care, feed, until incision healing;Ultrasonic detection is carried out, the inner diameter and blood flow velocity of the vertebral artery of rat model are obtained, compared with the inner diameter and blood flow velocity of the vertebral artery of the same age healthy rat or rat before modeling, whether it meets the standard of successful modeling is judged.

The invention relates to a colla corii asini-concha haliotidis compound as well as a preparation method and application thereof, and belongs to the technical field of medicines and health-care products. The colla corii asini-concha haliotidis compound provided by the invention comprises the following components in parts by weight: a) 38-42 parts of colla corii asini; b) 15-25 parts of concha haliotidis; and c) 1-5 parts of an auxiliary material, wherein the auxiliary material is selected from one or more of polyvinylpyrrolidone, copovidone, hydroxy propyl cellulose and hydroxyethyl cellulose. The donkey-hide gelatin and concha haliotidis compound is prepared by using a hot melt extrusion technology, so that the smell, wettability, dispersity and other properties of the donkey-hide gelatin are obviously improved, and the donkey-hide gelatin compound shows a good effect in an osteoporosis rat model and a calcium-deficient mouse model. The preparation process is simple and controllable, and has a good market prospect.

The invention belongs to the technical field of biomedicine, and particularly relates to an animal model and a modeling method thereof. According to the method, the northwest dryness syndrome type sub-health animal model is successfully constructed, an open model evaluation mode is adopted, and the established model is evaluated through goodness of fit; furthermore, autumn pear syrup is used for indicating that the prescription corresponds to the syndrome. The northwest dryness syndrome type sub-health target model established by the invention can provide a stable and reliable research model for external dryness syndrome essence exploration, arid region sub-health prevention and treatment, drug effect and pharmacological mechanism research of traditional Chinese medicines, prescriptions and the like with body resistance strengthening and dryness moistening effects, health product research and development and the like. An open model evaluation mode is adopted, and the higher the goodness of fit is, the closer the model to the northwest dryness syndrome type sub-health target model is. The northwest dryness syndrome type square domain dryness evil sub-health rat model is more suitable for arid region sub-health status research, and the northwest dryness syndrome type autumn cause dryness evil sub-health rat model is more suitable for autumn moistening health care research.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The invention discloses application of an HIF1A inhibitor in preparation of a medicine for preventing and / or treating hypertrophic cardiomyopathy, and belongs to the field of biological medicine. For a rat model of spontaneous hypertrophic cardiomyopathy caused by MYH7B gene knockout, hypertrophic cardiomyopathy can be significantly relieved by intraperitoneal injection of the HIF1A inhibitor LW6, heart remodeling can be relieved, heart functions can be improved, and myocardial hypertrophy caused by silent MYH7B genes can be effectively resisted by using siRNA of mRNA transcribed by the HIF1A gene. The key mechanism of the HIF1A inhibitor for treating the hypertrophic cardiomyopathy is that the hypertrophic cardiomyopathy is prevented and treated by reducing the expression level of glycolysis key enzymes GLUT1, HK2 and the like, inhibiting the formation and accumulation of cardiac lactic acid and improving the ventricular remodeling of the hypertrophic cardiomyopathy. The results show that the HIF1A inhibitor can be used for treating and / or preventing the human hypertrophic cardiomyopathy and has the potential of being developed into the medicine for clinically preventing and treating the hypertrophic cardiomyopathy.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

The invention discloses an application of N6022 in improving brain injury after cardiac arrest resuscitation, and particularly relates to an application of N6022 or a derivative thereof given through a nose in improving the brain injury after cardiac arrest resuscitation and increasing the survival rate after cardiac arrest resuscitation. Compared with the prior art, the application has the advantages that the increased GSNOR enzyme activity of brain tissues after sudden cardiac arrest resuscitation can be effectively inhibited by nasal injection of N6022 into a sudden cardiac arrest resuscitation rat model; the N6022 can effectively improve the neurological function after cardiac arrest resuscitation and increase the survival rate after cardio-pulmonary resuscitation; n6022 is used for inhibiting the activity of GSNOR, so that the number of survival neurons of brain tissues after sudden cardiac arrest resuscitation can be increased; the delivery mode of the N6022 through the nose can effectively enable the N6022 to enter the brain tissue of the rat. According to the invention, a new application field of N6022 is developed, and a meaningful reference is provided for improving the cerebral function after sudden cardiac arrest resuscitation.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention provides a manufacturing method of a silica-induced lung injury rat model and application of Erchen decoction. A manufacturing method of a silica-induced lung injury rat model is used for researching medical application and pathological effects of Erchen decoction in treatment of silicosis, traditional Chinese medicines in the Erchen decoction comprise Pinellia ternate, dried orange peel, Poria cocos, honey-fried licorice root, dark plum and ginger, and the manufacturing method is characterized by comprising the following steps: S1, experimental animals and grouping; the invention provides a manufacturing method of a silica-induced lung injury rat model and an application of Erchen soup, and systematically verifies and deepens a microecological mechanism of silicosis on the basis of early discovery; a new accurate diagnosis and treatment target is provided; the modern breakthrough of pharmacological research of traditional Chinese medicines is realized; the dysbacteriosis type silicosis model established by the invention has the advantages of simple and convenient modeling method, good repeatability, clear pathological characteristics and clear key target spots.

The invention discloses application of EDIL-3 in preparation of a medicine for repairing blood vessels in acute lung injury and application of ISX-9 in promotion of expression of EDIL-3 in mesenchymal stem cell exosomes. It is found for the first time that ISX-9 can promote expression of EDIL-3, and EDIL-3 overexpression can improve the ALI treatment capacity of MSCs-EXO, and it is proved that the lung action strength of EDIL-3 in the mesenchymal stem cell exosome is enhanced, and the ALI treatment capacity of the mesenchymal stem cell exosome is enhanced. The scheme has been verified in cell and rat ALI models, and has potential clinical application value.

The invention discloses application of clostridium butyricum based on clostridium butyricum with the product number of BNCC337239 in preparation of a medicine or food for treating and / or preventing polycystic ovarian syndrome, and a culture method of the clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the intragastric administration frequency is 1-3 times per week at the dosage of 0.1-0.5 mL / 100 g, and the intragastric administration lasts for 3-8 weeks, such that the estrus cycle disorder, the insulin resistance, the blood sex hormone disorder and the ovarian polycystic degeneration of the PCOS rat model can be significantly improved, and the method can be used for preparing the drug for treating the polycystic ovarian syndrome.

The invention relates to the technical field of biomedicine, in particular to an ELS-induced depression-like behavior rat whole-brain tissue lipid space metabolism analysis method which comprises the following steps: firstly, constructing an ELS-induced depression-like behavior rat model, and determining a depression model group by adopting a depression-like behavior test; then, taking a conventionally fed rat as a control group, respectively carrying out 2D scanning on the control group and the depression model group based on a mass spectrum space omics technology, constructing a 2D brain lipid map, and carrying out whole-brain 3D reconstruction to obtain brain tissue lipid mass spectrum imaging data; and finally, carrying out metabolic heterogeneity analysis on brain tissue lipid mass spectrum imaging data. The method provided by the invention aims to provide technical and data atlas support for research on a lipid metabolism disorder molecular mechanism of occurrence and development of early-stage negative stress induced depression from an animal model level, and meanwhile, the application range of a mass spectrum space omics technology is expanded.

The invention belongs to the technical field of new application of medicines, and provides application of Zhongwinning in preparation of a medicine for treating ischemic heart disease. In a myocardial ischemia rat model test, Zhongwinning shows that the Zhongwinning can obviously improve the left ventricular ejection fraction and the left ventricular short-axis shortening rate of a myocardial ischemia rat; in addition, the rising and falling rates of the ventricular pressure of the myocardial ischemia rats can be remarkably improved, and it is indicated that Zhongutanin can effectively recover the left ventricular systolic function and can effectively repair myocardial injury caused by myocardial ischemia reperfusion. Therefore, according to the experimental research result of the application, the Zhongwinning has a certain application prospect in treating the ischemic heart disease.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

The invention belongs to the technical field of pharmaceutical chemistry and natural product separation, and provides application of tribulus terrestris polysaccharide. The tribulus terrestris polysaccharide can be used for preparing drugs for treating hypertension. The tribulus terrestris polysaccharide has the effects of reducing blood pressure, relieving vascular endothelium pathological injury, improving vascular endothelium dysfunction and protecting vascular endothelium on a hypertensive rat model. The treatment effect of the fried tribulus terrestris polysaccharide is obviously superior to that of the tribulus terrestris polysaccharide, and meanwhile, the blood pressure reducing effect of the fried tribulus terrestris polysaccharide is not obviously different from that of a positive medicine valsartan. A new material basis is provided for development of antihypertensive drugs, and meanwhile the medicinal value of the tribulus terrestris polysaccharide is expanded.

The invention provides a construction method of a hypertension-cerebral hypoperfusion composite cerebral small vascular disease rat model. The construction method comprises the steps of experimental animal and grouping, hypertension model induction, cerebral hypoperfusion model induction and model evaluation system. According to the model, hereditary hypertension is replaced by 'L-NAME-induced drug-induced hypertension', and the model is combined with bilateral carotid artery occlusion surgery, so that clinical common hypertension and cerebral hypoperfusion dual pathological processes are successfully simulated. Compared with an SHR model, drug-induced hypertension is adopted to replace hereditary hypertension, and the method has the remarkable advantages in the aspects of period-cost-controllability-flux, 1, the modeling period is shortened to 8 weeks, and about 2 / 3 of time is saved; (2) the cost of a single animal is less than 1 / 3 of that of SHR, and the method is suitable for large-sample and multi-batch research; (3) the dosage of the L-NAME is adjustable, and the two-way intervention research of'hypertension driving 'and'blood pressure normalization' is supported; background data of the SD rats are complete and sufficient in supply, and multi-center repeated experiments are facilitated.

The invention discloses an iRGD-modified mesenchymal stem cell outer vesicle-loaded WZ35 dual-targeting drug delivery composition, which is characterized in that rat bone marrow mesenchymal stem cell-derived extracellular vesicles are used as carriers, curcumin analogues WZ35 are loaded in the carriers, and iRGD peptides are covalently modified on the surfaces of the carriers, so that passive targeting and active targeting synergistic delivery is realized; efficient entrapment of the medicine is achieved in an extrusion or co-incubation mode, the particle size of the obtained composition is 100-200 nm, and the dispersity is good; in-vivo experiments show that compared with free WZ35, the composition has the advantages that the enrichment efficiency of WZ35 in lung tissue is remarkably improved, right ventricular systolic pressure can be effectively reduced in an anoxia-induced pulmonary arterial hypertension rat model, pulmonary vascular remodeling is improved, and the invention provides a novel efficient and safe drug delivery strategy for targeted therapy of lung diseases.

The invention discloses a method for improving autism behaviors through Npas4 expression and overexpression in a cat chat syndrome model, and belongs to the technical field of animal model construction. Selecting SD wild rats and CdCS model rats, and normally feeding and breeding the rats; the method comprises the following steps: measuring the protein concentration by adopting a BCA method, then carrying out Western Blot, then carrying out brain stereotactic injection, and finally carrying out behavioral testing. According to the invention, a CdCS rat model is established by using a CRISPR-Cas9 technology, and the model shows cognitive and social behavior disorders and medial prefrontal cortex (mPFC) neuron dendritic abnormality; in addition, an abnormally expressed gene is found in the model mouse, the research focuses on Npas4, and a new insight is possibly provided for disease treatment.

The application belongs to the technical field of biology and specifically relates to a casein phosphopeptide for promoting calcium, iron and zinc mineral absorption and improving bone health. The application obtains the casein phosphopeptide containing high-activity peptide segments by optimizing the process, and takes six mineral elements of calcium, magnesium, copper, iron, zinc and manganese as research objects. Firstly, the mineral deficiency rat model is used to evaluate the mineral utilization of the CPP. The consumption of 7mg / kg.d increases the contents of Ca, Mg, Cu, Fe, Zn and Mn in femur by 7.12%, 3.56%, 20.76%, 15.84%, 9.94% and 67.12% respectively. Secondly, the molecular docking technology is used to screen the peptide segments with calcium absorption activity from the CPP and perform function verification. The application aims to reveal the effect of the CPP in the mineral absorption and utilization from the cell and animal levels, and provide a theoretical basis for the functional development.

This invention relates to the field of biomedical technology, and particularly to the application of crotonin A in the preparation of drugs for treating IgA nephropathy. Pharmacodynamic experiments conducted in vivo on a Thy1 rat model showed that crotonin A effectively reduced 24-hour urinary protein and the urinary protein-to-creatinine ratio in an IgA nephropathy model—an anti-Thy1 rat nephritis model—and inhibited the expression of mRNAs of genes related to renal cortical inflammation, proliferation, and fibrosis, including Cyclin E, α-SMA, FN, CCL2, NF-κB, and IL-6, further improving renal pathology. In in vitro cell models, crotonin A inhibited the proliferation of rat mesangial cells and suppressed the expression of mRNAs of TGF-β, Cyclin E, α-SMA, CCL2, NF-κB, and IL-6, indicating that crotonin A has significant anti-inflammatory, anti-cell proliferation, and anti-fibrotic effects. Brucella oleracea has considerable therapeutic potential, providing a potential new drug option for the clinical prevention and treatment of IgA nephropathy, and is of great significance for the development of safe and effective drugs for the treatment of IgA nephropathy.

This invention belongs to the field of novel pharmaceutical applications, providing the application of Zhongwu Ning in the preparation of drugs for treating ischemic heart disease. In rat models of myocardial ischemia, Zhongwu Ning significantly increased the left ventricular ejection fraction and left ventricular fractional shortening rate; it also significantly improved the rate of increase and decrease of intracardiac pressure in rats with myocardial ischemia, indicating that Zhongwu Ning can effectively restore left ventricular systolic function and effectively repair myocardial damage caused by myocardial ischemia-reperfusion. Therefore, based on the experimental research results of this application, Zhongwu Ning has certain application prospects in the treatment of ischemic heart disease.